Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 30 items

Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016

Abstract - Primary - Primary - GI - CALGB-80802

NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Preliminary - GI - NCCTG-N044J

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)

Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-80303

Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study

Cohen, Romain , Shi, Qian , Meyers, Jeff , Jin, Zhaohui ... - ASCO GI - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702

Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000

Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Primary - Primary - GI - ACOSOG-Z9000

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative Science from CALGB 80802

Dercle, Laurent , Geyer, Susan , Nixon, Andrew , Innocenti, Federico ... - ASCO GI - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802

Alliance/CALGB 80802 impact of hepatitis c (HCV) on doxorubicin (D) + sorafenib (S) vs. s in patients (pts) advanced HCC (aHCC)

Dika, Imane El , Geyer, Susan M. , Nixon, Andrew ... - ASCO GI - J Clin Oncol - 2021

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802

Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202.

Geyer, Susan M. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO GI - J Clin Oncol - 2021

Abstract - Secondary - Primary - GI - A021202

Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)

Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017

Abstract - Primary - Preliminary - GI - CALGB-80803

Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Secondary - Primary - GI - NCCTG-N9741

Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance)

Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017

Abstract - Secondary - Preliminary - GI - CALGB-80405

Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer.

Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Primary - GI - NCCTG-N0349

On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)

Hatch, Ace J. , Ou, Fang-Shu , Zemla, Tyler , Liu , Star, Mark D. ... - ASCO GI - J. Clin. Oncol - 2019

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147

Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011

Abstract - Primary - Primary - GI - N0147

A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?

In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - ASCO GI - J Clin Oncol - 2018

Abstract - Primary - Primary - Disparities - Pilot

Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas

Katz, Matthew , Shi, Qian , Meyers, Jeff , Herman, Joseph M. ... - ASCO GI - J Clin Oncol - 2021

Abstract - Primary - Primary - GI - A021501

Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer

Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Primary - Long-Term-Followup - GI - NCCTG-N0349

Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer.

Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010

Abstract - Secondary - Primary - GI - NCCTG-N994C

HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance)

Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Correl Sci NOS - N0147

Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer

Mcwilliams, R. , Goetz, M. , Morlan, B. , Salim, M. , Rowland, K., Jr ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Primary - GI - NCCTG-N0341

Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB)

Meropol, N. J. , Niedzwiecki, D. , Shank, B. , Colacchio, T. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2005

Abstract - Primary - Primary - GI - CALGB-9281

Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114.

Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Goldberg, R. M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2009

Abstract - Secondary - Primary - GI - INT-0114

Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis

Miller, R. C. , Petereit, D. G. , Sloan, J. A. , Liu, H. ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Symptom Inter - N08C9

Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB 80405 (Alliance)

Ng, Kimmie , Venook, Alan P. , Sato, Kaori , Hollis, Bruce W. ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - GI - CALGB-80405

Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741.

Sargent, D. J. , Campbell, M. E. , Grothey, A. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Secondary - Primary - GI - NCCTG-N9741

Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance)

Sehdev, Amikar , Niedzwiecki, Donna , Venook, Alan P. ... - ASCO GI - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair.

Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010

Abstract - Secondary - Primary - GI - NCCTG-N994C

Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Utilizing cultural and ethnic variables in a survey to identify individuals at high risk for gastric cancer

Solsky, I. , Parides, M. , Schechter, C. , Rapkin, B. ... - ASCO GI - J Clin Oncol. - 2019

Abstract - Primary - Primary - Disparities - Pilot

Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival CALGB 89803 (Alliance)

Van Blarigan, Erin L , Fuchs, Charles S. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017

Abstract - Secondary - Primary - GI - CALGB-89803